In order to further discuss whether the PI3K/AKT pathway affects ZO‐1, Twist and MMP‐2/9 production in GBM cells treated with IL‐17A, a PI3K/AKT inhibitor (LY294002) was used to treat U251 and U87 cells before IL‐17A was applied. This evidence concerns the gene AKT1 and glioblastoma.